UroToday

ESMO 2025: Discussant – PR.21 and LUNAR Trials

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics proffered paper session. Dr. Karolien Goffin discussed the previously ...
UroToday

ESMO 2025: Emerging New Therapeutic Strategies for Advanced Prostate Cancer

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...
UroToday

ESMO 2025: Final Results of the COTRIMS (COlogne Trial of Retroperitoneal Lymphadectomy in Metastastic Seminoma) Trial

Follow-up was done according to EAU guidelines. In 27 patients mIR-371 was evaluated preoperatively and correlated with ...
UroToday

ESMO 2025: Enfortumab Vedotin with Pembrolizumab Treatment Outcomes in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of th…

The study investigators concluded that EV+P demonstrated activity in advanced urothelial carcinoma tumors with histologic ...
UroToday

ESMO 2025: Efficacy of [177Lu]Lu-PSMA-617 in Patients with Metastatic Clear Cell Renal Cell Carcinoma: a Multicentre Single-Arm Phase II Trial (RENALUT)

RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...
UroToday

ESMO 2025: Optimized Use of Endocrine Therapies and Chemotherapies in mCRPC

Among 804 androgen receptor pathway inhibitor-experienced mCRPC patients, 459 patients (57.1%) received another androgen receptor pathway inhibitor as their index therapy and 192 (23.9%) received ...
UroToday

ESMO 2025: Durability of Complete Response to First Line in Metastatic Renal Cell Carcinoma in the Real World

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between October 17 th and 21 st was host to the Poster presentation session. Dr. J. Connor ...
UroToday

ESMO 2025: Germline and Somatic Genetic Testing in Advanced Prostate Cancer: Practical Considerations and Challenges

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...
UroToday

ESMO 2025: Impact of Androgen Deprivation Therapy (ADT) on KLK2 mRNA Expression and Immunologic Correlates Across Prostate Cancer (PC) Disease States

KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage and grade. It exits in both secreted and membrane-associated forms, with ...
UroToday

ESMO 2025: Optimized Use of Immunotherapy and Targeted Therapies in mCRPC

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Aurelius Omlin discussing optimized use of immunotherapy and targeted ...
UroToday

ESMO 2025: Final Analysis of Lenvatinib + Pembrolizumab versus Sunitinib in Patients with Advanced RCC with or Without Bone Metastases in CLEAR

As such, at ESMO 2025, the investigators analyzed patients with or without baseline bone metastases treated with lenvatinib + pembrolizumab versus sunitinib in the CLEAR study with ∼4 years follow-up ...
UroToday

ESMO 2025: IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC

Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): A multicentre, open-label, randomized, phase 3 trial. Lancet ...